Skip to main content
Jagsonpal Pharmaceuticals Limited logo

Jagsonpal Pharmaceuticals Limited — Investor Relations & Filings

Ticker · JAGSNPHARM ISIN · INE048B01035 BSE.NS Manufacturing
Open in API
Filings indexed 1,048 across all filing types
Latest filing 2026-05-04 Call Transcript
Country IN India
Listing BSE.NS JAGSNPHARM

About Jagsonpal Pharmaceuticals Limited

https://www.jagsonpal.com/

Jagsonpal Pharmaceuticals Limited specializes in the development, manufacturing, and marketing of a diverse range of pharmaceutical formulations. The company maintains a significant focus on therapeutic segments including gynecology, orthopedics, and pain management. Its product portfolio features established brands in women's healthcare, particularly in the areas of pregnancy care and hormonal therapy, as well as treatments for bone health and inflammatory conditions. The organization leverages its research and development capabilities to introduce specialized formulations that address specific medical needs in its core therapeutic areas. By maintaining an extensive distribution network, the company ensures the accessibility of its products to healthcare professionals and patients, focusing on quality and therapeutic efficacy across its specialized product lines.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is titled as an "Earnings Call Transcript" for Jagsonpal Pharmaceuticals Limited for Q4 FY26, held on April 28, 2026. It contains a detailed transcript of the earnings conference call including management commentary on quarterly and full-year financial results, operational performance, strategic outlook, and a Q&A session with analysts. The text includes financial figures such as revenue, EBITDA, PAT, margins, cash position, buyback and dividend announcements, and forward-looking statements. The presence of a full transcript of the earnings call with management discussion and Q&A clearly identifies this as a Call Transcript (CT). The document length is substantial (15,000 characters), and it is not merely an announcement or a brief summary, but the full transcript itself. Therefore, the correct classification is Call Transcript (CT) with high confidence.
2026-05-04 English
Newspaper Advertisement- Extract of Audited Financial Results for FY 26
Regulatory Filings Classification · 82% confidence The document is a stock‐exchange submission under SEBI LODR Regulation 47 providing “Extracts of Audited Financial Results” as published in newspapers for the quarter and year ended March 31, 2026. It is not the full Annual Report or stand‐alone audit report, nor a detailed investor presentation or earnings transcript. It is a routine regulatory announcement/compliance filing to the exchanges. Thus it falls under general regulatory filings (RNS).
2026-04-29 English
Submission of Public Announcement pertaining to Buy back of Shares of Company published in the newspaper along with Board and Shareholder Resolution
Transaction in Own Shares Classification · 95% confidence The document is a detailed public announcement regarding the buyback of equity shares by Jagsonpal Pharmaceuticals Limited. It includes the approval of the buyback by the Board of Directors and shareholders, details of the buyback size, price, regulatory compliance references (SEBI Buyback Regulations, Companies Act), and procedural resolutions passed by the Board. The document also mentions the publication of the public announcement in newspapers and includes a certified true copy of the Board resolution. The content is focused on the announcement and procedural details of the buyback, not on financial results or earnings, nor is it a full financial report or audit. It is not a report publication announcement since it contains substantive details of the buyback plan and resolutions. Therefore, the document fits best under the category of Transaction in Own Shares (POS), which covers company announcements about share buybacks or repurchases.
2026-04-29 English
Copy of Newspaper Publication
Transaction in Own Shares Classification · 95% confidence The document is a formal Public Announcement under SEBI Buy‐Back Regulations notifying stock exchanges and shareholders of the company’s proposal to repurchase (buy back) up to 1,600,000 equity shares. It is not an earnings release or annual report, nor a management or policy document. It specifically relates to the company buying back its own shares, fitting the “Transaction in Own Shares” category.
2026-04-29 English
Copy of Newspaper Publication
Report Publication Announcement Classification · 95% confidence The document is a letter from Jagsonpal Pharmaceuticals Ltd dated April 29, 2026, addressed to stock exchanges (BSE and NSE) regarding the publication of an extract of audited financial results for the quarter and financial year ended March 31, 2026. It mentions that copies of the advertisement published in newspapers are enclosed. The document is essentially an announcement of the publication of financial results extracts, not the full financial report itself. The length is about 6,119 characters, which is relatively short and consistent with an announcement rather than a full report. There is no detailed financial data or comprehensive financial statements included in the text. Therefore, according to the "Menu vs Meal" rule, this document should be classified as a Report Publication Announcement (RPA) rather than an Annual Report (10-K) or Interim Report (IR).
2026-04-29 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice dated April 28, 2026, informing about the availability of the audio recording of the Q4 FY26 Earnings Conference Call of Jagsonpal Pharmaceuticals Limited. It references the earnings call and provides a link to the recording on the company's website. The document does not contain actual financial data or detailed financial results but is an announcement related to the earnings call. According to the rules, such announcements about availability of call recordings or materials are classified as Call Transcript (CT) if they contain the transcript itself, but since this is only an announcement of the recording availability and not the transcript, it is best classified as Regulatory Filings (RNS) as a fallback for miscellaneous regulatory announcements. The document length is short (1741 characters), and it does not contain the transcript or financial data itself, so it is not an Earnings Release (ER) or Interim Report (IR). Therefore, the appropriate classification is Regulatory Filings (RNS).
2026-04-28 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.